AbbVie (NYSE:ABBV) announces positive results from a Phase 3 clinical trial, SELECT-PsA 1,
evaluating RINVOQ (upadacitinib) in adults with psoriatic arthritis
(PA) who failed to respond adequately to or were intolerant of DMARD
(disease modifying anti-rheumatic drug) therapy.
The study met the primary endpoint demonstrating a
statistically significant proportion of treated patients achieving
ACR20 (20% improvement in PA) at week 12 versus placebo. Specifically,
71% and 79% of participants receiving 15 mg and 30 mg, respectively, of
RINVOQ achieved ACR20 compared to 36% in the control arm (p<0.0001).
Both doses of RINVOQ demonstrated non-inferiority
to Humira (adalimumab) as measured by ACR20 at week 12 while the 30 mg
dose also showed superiority.
No new safety signals were observed.
A sister Phase 3, SELECT-PsA 2, was also successful.
Results will be submitted for presentation at a future medical conference and publication.
The FDA approved the JAK inhibitor in August 2019 for rheumatoid arthritis.
Shares up 1% premarket on light volume.
https://seekingalpha.com/news/3538534-abbvies-rinvoq-successful-in-second-late-stage-psoriatic-arthritis-study
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.